Introduction

 

November 2, 2010
  • Rosa presents at CHEST 2010 meeting
  • Rosa will present two posters at the American College of Chest Physicians annual CHEST meeting for 2010 in Vancouver, BC. The posters will be presented on November 2 and 3. The first (Nov 2), entitled "Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling and Simulation Support the Novelty of MN-221, a Highly-Selective Beta2-Adrenergic Agonist for Treatment of Acute Asthma", will be presented in the 12:45 to 2 pm section on Asthma Treatments (see Abstract). The second poster (Nov 3), entitled "Pharmacokinetics and Pharmacodynamics of MN 221, a Novel Highly-Selective Beta2-Adrenergic Agonist for Treatment of Acute Chronic Obstructive Pulmonary Disease", will be presented in the 12:45 to 2 pm section on COPD II (see Abstract). In both studies, modeling was used to predict drug efficacy in clinical trials for acute asthma and COPD, respectively. Both posters will be available in the CHEST online supplement in October 2010. We will post links to both presentations on this website when allowed by embargo regulations.

October 5, 2009
  • Rosa launches updated website
  • Rosa has launched its updated website to better reflect the breadth of its offerings and the depth of its experience. In the coming weeks, we will be revising our case studies and adding new ones, providing examples of models, and adding a list of selected clients. Please check back often for more news. In the meantime, if you have specific questions, please contact us.

October 4, 2009
  • Rosa presents PK/PD poster “PK Modeling, Simulation, and Scaling of Adult and Pediatric Data to Support International Regulatory Submissions” at the 2009 American College of Pharmacometrics (ACoPs) annual meeting.
  • This poster describes the use of modeling to predict therapy outcomes for European Medicines Agency (EMEA)-approved dose regimens, based on data from the US and US-approved dose regimens. The modeling allowed approval in the EMEA without additional clinical trials.

July 15, 2009 
  • Rosa’s PK/PD Modeling dramatically alters dose selection for proof-of-concept trial.
  • Rosa’s modeling of complex respiratory data for an emerging publicly-held pharmaceutical company showed that an unexpectedly large number of non-responders in a trial arm was responsible for a counter-intuitive dose-response curve. In addition, the modeling showed that the cardiovascular risk was not as high as had been thought initially. The modeling process allowed the company to convince investors and investigators to continue with a significantly higher dose, averting not only the waste of a trial but possibly the failure of the company.

May 1, 2009 
  • Cofounder Ron Beaver, PhD assumes roles of Chairman, President, and CEO.

June 19, 2008
  • Rosa and Merck & Co., Inc. jointly present the PhysioPD™ poster “Alteration of glucose and insulin regulatory networks in Type 2 diabetes mellitus” at Population Approach Group in Europe (2008).
  • This poster describes a substantial collaboration in which a quantitative PhysioPD model of the (patho)physiological mechanisms and pathways that underlie type 2 diabetes mellitus was developed to characterize the pharmacological and toxicological attributes of single or multiple compound/target pairs. The ultimate goal of the modeling was to identify the impact of altered pharmacokinetics and the pharmacokinetic-pharmacodynamic relationship on target populations and lead optimization. Reference: PAGE 17 (2008) Abstr 1375 [www.page-meeting.org/?abstract=1375]